MOLN
Molecular Partners AG
$
4.085
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.720
Open
3.980
VWAP
4.35
Vol
80.70K
Mkt Cap
150.59M
Low
3.800
Amount
350.91K
EV/EBITDA(TTM)
--
Total Shares
33.18M
EV
14.10M
EV/OCF(TTM)
--
P/S(TTM)
--
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.280
-6.67%
--
--
0.000
-100%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for Molecular Partners AG (MOLN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 11.92%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+11.92%
In Past 3 Month
3 Analyst Rating
103.92% Upside
Wall Street analysts forecast MOLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOLN is 8.33 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
103.92% Upside
Current: 4.085
Low
4.00
Averages
8.33
High
12.00
103.92% Upside
Current: 4.085
Low
4.00
Averages
8.33
High
12.00
JPMorgan
Richard Vosser
Neutral
downgrade
$4
2025-09-03
Reason
JPMorgan
Richard Vosser
Price Target
$4
2025-09-03
downgrade
Neutral
Reason
JPMorgan analyst Richard Vosser lowered the firm's price target on Molecular Partners to $4 from $4.50 and keeps a Neutral rating on the shares.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Molecular Partners AG (MOLN.O) is -2.39, compared to its 5-year average forward P/E of -3.42. For a more detailed relative valuation and DCF analysis to assess Molecular Partners AG 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.42
Current PE
-2.39
Overvalued PE
2.53
Undervalued PE
-9.36
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
5.00
Current EV/EBITDA
-0.02
Overvalued EV/EBITDA
40.56
Undervalued EV/EBITDA
-30.56
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
29.80
Current PS
2.92
Overvalued PS
72.47
Undervalued PS
-12.88
Financials
Annual
Quarterly
FY2025Q3
YoY :
-100.00%
0.00
Total Revenue
FY2025Q3
YoY :
-18.23%
-11.93M
Operating Profit
FY2025Q3
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q3
YoY :
-32.65%
-0.33
EPS - Diluted
FY2025Q3
YoY :
-24.94%
-9.52M
Free Cash Flow
FY2025Q3
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q3
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q3
YoY :
-100.00%
N/A
Net Margin - %
FY2025Q3
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
3
6.1M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MOLN News & Events
Events Timeline
2025-08-21 (ET)
2025-08-21
05:11:45
Molecular Partners names Martin Steegmaier as its new chief scientific officer.
2025-06-11 (ET)
2025-06-11
16:03:53
Molecular Partners to preent updated data from MP0533 trial at EHA congress
2025-06-10 (ET)
2025-06-10
05:29:35
Molecular Partners to reduce workforce by 24%
Sign Up For More Events
Sign Up For More Events
News
9.0
11-03Yahoo FinanceMolecular Partners to Showcase New Data from Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
4.0
09-03BenzingaJP Morgan Keeps Neutral Rating on Molecular Partners, Reduces Price Target to $4
2.0
08-26BenzingaEHang, Molecular Partners, and Other Major Stocks Decline in Tuesday's Pre-Market Trading
Sign Up For More News
People Also Watch
BRLT
Brilliant Earth Group Inc
2.415
USD
+0.21%
TCX
Tucows Inc
18.860
USD
-1.57%
IKT
Inhibikase Therapeutics Inc
1.600
USD
+8.84%
CYBN
Cybin Inc
6.730
USD
-7.30%
BTOC
Armlogi Holding Corp
0.579
USD
-6.92%
BIOA
BIOAGE Labs Inc
7.420
USD
-1.98%
NOTE
FiscalNote Holdings Inc
4.010
USD
-2.20%
CMCL
Caledonia Mining Corporation PLC
28.270
USD
+0.53%
MRCC
Monroe Capital Corp
7.000
USD
+0.29%
FAQ
What is Molecular Partners AG (MOLN) stock price today?
The current price of MOLN is 4.085 USD — it has increased 12.41 % in the last trading day.
What is Molecular Partners AG (MOLN)'s business?
What is the price predicton of MOLN Stock?
What is Molecular Partners AG (MOLN)'s revenue for the last quarter?
What is Molecular Partners AG (MOLN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Molecular Partners AG (MOLN)'s fundamentals?
How many employees does Molecular Partners AG (MOLN). have?